The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes for the 2025 National Health Insurance Drug Catalog. Six drugs had their review status changed, all involving the Basic Health Insurance Drug Catalog.
Key Drug Status Changes
Drug
New Review Result
Reason / Criteria Met
Risperidone Microspheres for Injection
Failed
–
Triptorelin Pamoate for Injection
Failed
–
Levodopa Injection
Passed
Meets Criteria 5 (rare‑disease drug approved before 30 Jun 2025)
Calcium Gluconate and Sodium Chloride Injection
Passed
Meets Criteria 2 (new or significantly changed indication approved 01 Jan 2020‑30 Jun 2025)
Ceftriaxone Sodium and Sulbactam Sodium for Injection
Passed
Meets Criteria 2 (new/changed indication)
Ursodeoxycholic Acid Oral Suspension
Passed
Meets Criteria 1, 4, 5 (new generic name within 5 years; encouraged R&D; rare‑disease drug approved before 30 Jun 2025)
2025 Catalog Application Totals
Catalog
Total Applications
Generic Drug Names
Passed
Out‑of‑Catalog
In‑Catalog
Basic Health Insurance
718
633
535
311
224
Commercial Insurance Innovative
141
141
121
—
—
Both Catalogs
—
—
—
79
—
What This Means for Stakeholders
Pharmaceutical Companies: 535 approvals out of 718 submissions indicate a high but selective acceptance rate; companies must strengthen evidence for rare‑disease and indication‑change submissions.
Healthcare Providers: New approvals for Levodopa, Ceftriaxone/Sulbactam, and Ursodeoxycholic Acid expand therapeutic options, particularly for rare diseases and chronic conditions.
Patients & Payers: A larger pool of approved drugs enhances coverage choices, potentially reducing out‑of‑pocket costs for chronic treatments.-Fineline Info & Tech
By Fineline Cube 